Published: May 06, 2021
LONDON, May 06, 2021 (GLOBE NEWSWIRE) Autolus plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the quarter ended March 31, 2021.
“We have had a productive first quarter and are on track for multiple clinical read outs during the remainder of this year and into 2022,” said Dr. Christian Itin, chief executive officer of Autolus. “We are excited by the unique characteristics of AUTO1 and encouraged by what we believe is the significant clinical benefit AUTO1 can offer for patients with relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (ALL). AUTO1 is being evaluated in the P1b/2 FELIX study in adult ALL patients with data expected in 2022. In addition, AUTO1 is being explored in patients with B-NHL and in primary CNS lymphoma, and we are also evaluating AUTO1/22 in pediatric ALL patients. Finally, several programs a
06 May 2021 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes that its portfolio company, Autolus Therapeutics Plc (NASDAQ: AUTL) (Autolus), announced its operational and financial results for the first quarter ended March 31, 2021. The announcement can be accessed on Autolus investor website at https://www.autolus.com/investor-relations and full text of the announcement from Autolus is contained below. Autolus management will host a conference call today, at 8:30 a.m. EDT/ 1:30pm GMT to discuss the company s financial results and operational update. To listen to the webcast and view the accompanying slide presentation, please go to:
Semler to Report First Quarter 2021 Financial Results and Host Conference Call on May 3, 2021
News provided by
Share this article
Share this article
SANTA CLARA, Calif., April 26, 2021 /PRNewswire/ Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the first quarter ended March 31, 2021 after the close of U.S. financial markets on Monday, May 3, 2021. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Andrew Weinstein, senior vice president, finance and accounting, and Dennis Rosenberg, chief marketing officer, will join him on the call.
Investegate |Syncona Limited Announcements | Syncona Limited: Autolus appoints non-executive Chair investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Semler to Participate in the 20th Annual Needham Virtual Healthcare Conference
News provided by
Share this article
Share this article
SANTA CLARA, Calif., April 7, 2021 /PRNewswire/ Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its chief executive officer, Doug Murphy-Chutorian, and chief marketing officer, Dennis Rosenberg, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, at 4:30 pm ET. Management will also participate in one-on-one calls with investors.
A live webcast will be available under Events and Presentations on the Investor Info section of the Semler Scientific website and may be accessed through the following link: https://wsw.com/webcast/needham107/smlr/2276780. The presentation will be archived for a period of 90 days after the conference.